SCHEMBL2657795

SCHEMBL2657795

COc1cccc(-c2cccc3c(N)c4c(nc23)CN(C2CCC2)C4=O)n1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HSP90AA1 P07900 5/20 0.39
▸ HSP90AB1 P08238 5/20 0.39
▸ BTK Q06187 1/20 0.35
▸ TRAP1 Q12931 1/20 0.35
▸ NPY1R P25929 1/20 0.35
▸ NPY5R Q15761 1/20 0.35
▸ BACE1 P56817 1/20 0.35
▸ POLB P06746 1/20 0.34
▸ PARP1 P09874 1/20 0.34
▸ HTT P42858 1/20 0.34
▸ ESR2 Q92731 1/20 0.34
▸ GRM5 P41594 1/20 0.32
▸ GRM1 Q13255 1/20 0.32
▸ HRH3 Q9Y5N1 1/20 0.32
▸ TGFBR1 P36897 1/20 0.32
▸ APLNR P35414 3/20 0.32
▸ BMPR1A P36894 1/20 0.32
▸ ACVRL1 P37023 1/20 0.32
▸ ACVR1 Q04771 1/20 0.32
▸ PARP2 Q9UGN5 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2669400 0.87 PIK3CA (0.35) HSP90AA1HSP90AB1NPY1RNPY5RPOLB
SCHEMBL4911805 0.87 BRD9 (0.40) NPY1RNPY5RPOLBPARP1HTT
SCHEMBL2659903 0.85 BRD9 (0.40) NPY1RNPY5RPOLBPARP1HTT
SCHEMBL2669426 0.85 NPY1R (0.40) NPY1RNPY5RPOLBHRH3
SCHEMBL4916106 0.85 NPY1R (0.42) NPY1RNPY5RPOLBHRH3
SCHEMBL2669535 0.84 PIK3CA (0.46) —
SCHEMBL2669397 0.84 GABRG2 (0.38) NPY1RNPY5RPOLBPARP1HTT
SCHEMBL2669394 0.83 GRM5 (0.36) POLBPARP1HTTESR2GRM5
SCHEMBL8109335 0.83 NPY1R (0.39) NPY1RNPY5RPOLBGRM5HRH3
SCHEMBL4921068 0.83 NPY1R (0.39) NPY1RNPY5RPOLBHRH3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US claimed
EP-2176263-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS AstraZeneca AB (SE) 2010-04-21 — — EP disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318943-A1 Compounds and Uses Thereof - 848 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed
WO-2008155572-A2 FUSED QUINOLINE DERIVATIVES USEFUL AS GABA MODULATORS ASTRAZENECA AB (SE) 2008-12-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080318943-A1 Compounds and Uses Thereof - 848 COMT, BACE1, BDNF HSP90AA1 4097/4885HSP90AB1 4007/4885BTK 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback